LT2968173T - Heterocikliniai junginiai ir jų panaudojimas - Google Patents

Heterocikliniai junginiai ir jų panaudojimas

Info

Publication number
LT2968173T
LT2968173T LTEP14719472.4T LT14719472T LT2968173T LT 2968173 T LT2968173 T LT 2968173T LT 14719472 T LT14719472 T LT 14719472T LT 2968173 T LT2968173 T LT 2968173T
Authority
LT
Lithuania
Prior art keywords
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
LTEP14719472.4T
Other languages
English (en)
Inventor
Mingda Bi
Robert KUEHL
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2968173(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of LT2968173T publication Critical patent/LT2968173T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEP14719472.4T 2013-03-14 2014-03-14 Heterocikliniai junginiai ir jų panaudojimas LT2968173T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
PCT/US2014/027104 WO2014152236A1 (en) 2013-03-14 2014-03-14 Heterocyclic compounds and their uses

Publications (1)

Publication Number Publication Date
LT2968173T true LT2968173T (lt) 2021-03-25

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
LT14720369T LT2970123T (lt) 2013-03-14 2014-03-14 Omekamtivo mekarbilo druska ir jos gamybos būdas
LTEP14719472.4T LT2968173T (lt) 2013-03-14 2014-03-14 Heterocikliniai junginiai ir jų panaudojimas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LT14720369T LT2970123T (lt) 2013-03-14 2014-03-14 Omekamtivo mekarbilo druska ir jos gamybos būdas

Country Status (41)

Country Link
US (14) US9951015B2 (lt)
EP (3) EP2970123B1 (lt)
JP (5) JP6783138B2 (lt)
KR (2) KR102374159B1 (lt)
CN (3) CN105120844A (lt)
AP (1) AP2015008789A0 (lt)
AR (2) AR095542A1 (lt)
AU (2) AU2014240049C1 (lt)
BR (2) BR112015022857B1 (lt)
CA (3) CA2902436A1 (lt)
CL (1) CL2015002708A1 (lt)
CR (1) CR20150549A (lt)
CY (2) CY1122695T1 (lt)
DK (2) DK2970123T3 (lt)
EA (1) EA031185B1 (lt)
ES (2) ES2837038T3 (lt)
HK (4) HK1218080A1 (lt)
HR (2) HRP20191728T1 (lt)
HU (2) HUE052355T2 (lt)
IL (2) IL240788B (lt)
JO (1) JOP20140114B1 (lt)
LT (2) LT2970123T (lt)
MA (2) MA44637B1 (lt)
ME (1) ME03566B (lt)
MX (3) MX363347B (lt)
MY (1) MY186048A (lt)
NZ (1) NZ711225A (lt)
PE (1) PE20151786A1 (lt)
PH (2) PH12015501998B1 (lt)
PL (2) PL2968173T3 (lt)
PT (2) PT2968173T (lt)
RS (2) RS61215B1 (lt)
RU (1) RU2663663C2 (lt)
SA (1) SA515361088B1 (lt)
SG (2) SG10201706656RA (lt)
SI (2) SI2970123T1 (lt)
TN (1) TN2015000380A1 (lt)
TW (1) TWI667026B (lt)
UA (1) UA117011C2 (lt)
UY (1) UY35449A (lt)
WO (2) WO2014152236A1 (lt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35449A (es) * 2013-03-14 2014-09-30 Amgen Inc Compuestos heterocíclicos y sus usos
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
EP3313444B1 (en) 2015-06-26 2020-10-21 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
SI3645518T1 (sl) * 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
BR112019028046A2 (pt) * 2017-06-30 2020-07-07 Amgen Inc. métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
HUE052049T2 (hu) * 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
US20220185791A1 (en) * 2019-03-12 2022-06-16 Amgen Inc. Polymorphs of a cardiac troponin activator
KR20220002885A (ko) * 2019-03-12 2022-01-07 암젠 인크 심장 트로포닌 활성제의 다형체 및 공결정
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) * 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CN115279349A (zh) * 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
CA3200673A1 (en) 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
MX2023010558A (es) 2021-03-10 2023-11-24 Amgen Inc Sintesis de omecamtiv mecarbil.
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) * 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
JP4100910B2 (ja) 1999-12-23 2008-06-11 ファイザー・プロダクツ・インク ヒドロゲル駆動の薬物剤形
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
JP2005531492A (ja) 2001-10-17 2005-10-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高リスク患者のｉｉ型糖尿病を低減させる方法
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
MXPA06014495A (es) 2004-06-17 2007-03-01 Cytokinetics Inc Compuestos, composiciones y metodos.
WO2007054975A1 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
PE20070823A1 (es) * 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
EP2349284B1 (en) 2008-10-03 2016-11-23 Pericor Therapeutics, Inc. Treatment of acute decompensated heart failure
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
EP2968180B1 (en) * 2013-03-14 2019-04-24 Amgen Inc. Heterocyclic compounds and their uses
UY35449A (es) 2013-03-14 2014-09-30 Amgen Inc Compuestos heterocíclicos y sus usos
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3313444B1 (en) 2015-06-26 2020-10-21 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
SI3645518T1 (sl) 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
BR112019028046A2 (pt) 2017-06-30 2020-07-07 Amgen Inc. métodos de tratamento da insuficiência cardíaca com ativadores de sarcômeros cardíacos
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
MX2021001792A (es) 2018-08-17 2021-05-27 Amgen Inc Sales y formas cristalinas de omecamtiv mecarbil.
US20220042055A1 (en) 2018-12-18 2022-02-10 Amgen Inc. Method of reducing aromatic nitro compounds
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CN115279349A (zh) 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
CA3200673A1 (en) 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
MX2023010558A (es) 2021-03-10 2023-11-24 Amgen Inc Sintesis de omecamtiv mecarbil.

Also Published As

Publication number Publication date
US11384053B2 (en) 2022-07-12
ES2837038T3 (es) 2021-06-29
HRP20201967T1 (hr) 2021-03-05
LT2970123T (lt) 2019-11-11
US20140309235A1 (en) 2014-10-16
AR129504A2 (es) 2024-09-04
AU2014240049C1 (en) 2019-03-07
HK1218512A1 (zh) 2017-02-24
DK2970123T3 (da) 2019-10-21
HRP20191728T1 (hr) 2019-12-13
MA44637A1 (fr) 2019-08-30
CR20150549A (es) 2016-01-04
PE20151786A1 (es) 2015-12-11
MY186048A (en) 2021-06-17
US20160016906A1 (en) 2016-01-21
DK2968173T3 (da) 2020-12-21
IL241089B (en) 2019-10-31
AU2014239995B2 (en) 2018-07-26
AR095542A1 (es) 2015-10-21
AP2015008789A0 (en) 2015-10-31
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
CA3147180C (en) 2024-04-23
KR20220045014A (ko) 2022-04-12
SI2968173T1 (sl) 2021-04-30
US10421726B2 (en) 2019-09-24
JP7174132B2 (ja) 2022-11-17
SG10201706656RA (en) 2017-09-28
PT2968173T (pt) 2020-12-18
US20180273479A1 (en) 2018-09-27
US9988354B2 (en) 2018-06-05
CN105209437B (zh) 2018-09-18
MX2015012414A (es) 2016-04-25
US20200331859A1 (en) 2020-10-22
MA38399A1 (fr) 2017-01-31
CA2902436A1 (en) 2014-09-25
MX2021001231A (es) 2021-04-12
SA515361088B1 (ar) 2018-07-22
US11884630B2 (en) 2024-01-30
JP2019059746A (ja) 2019-04-18
UY35449A (es) 2014-09-30
AU2014240049A1 (en) 2015-09-10
SG11201507258PA (en) 2015-10-29
ME03566B (me) 2020-07-20
CA2902646A1 (en) 2014-09-25
PH12015501998A1 (en) 2016-01-11
HUE052355T2 (hu) 2021-04-28
US20220298114A1 (en) 2022-09-22
WO2014152270A1 (en) 2014-09-25
CN108785265A (zh) 2018-11-13
EP3821882A1 (en) 2021-05-19
EP2970123B1 (en) 2019-08-14
US20180312469A1 (en) 2018-11-01
HK1219484A1 (zh) 2017-04-07
JP2016519071A (ja) 2016-06-30
TN2015000380A1 (en) 2017-01-03
RU2015143643A (ru) 2017-04-18
IL240788A0 (en) 2015-10-29
AU2014239995A1 (en) 2015-09-10
JP6498658B2 (ja) 2019-04-10
MA38399B2 (fr) 2020-12-31
SI2970123T1 (sl) 2019-12-31
HK1218080A1 (zh) 2017-02-03
IL240788B (en) 2020-09-30
TW201524507A (zh) 2015-07-01
US20240317687A1 (en) 2024-09-26
US20200277261A1 (en) 2020-09-03
ES2750676T3 (es) 2020-03-26
CN108785265B (zh) 2024-10-08
JP2020125307A (ja) 2020-08-20
CA2902646C (en) 2022-08-16
US20200399221A1 (en) 2020-12-24
JP6689942B2 (ja) 2020-04-28
KR102374159B1 (ko) 2022-03-15
EP2968173B1 (en) 2020-10-14
JP2022023891A (ja) 2022-02-08
WO2014152236A1 (en) 2014-09-25
US20240101517A1 (en) 2024-03-28
HK1218544A1 (zh) 2017-02-24
UA117011C2 (uk) 2018-06-11
US20200079736A1 (en) 2020-03-12
JOP20140114B1 (ar) 2021-08-17
NZ711225A (en) 2020-06-26
US20240217933A1 (en) 2024-07-04
IL241089A0 (en) 2015-11-30
BR112015022857B1 (pt) 2022-10-25
PH12015501998B1 (en) 2016-01-11
HUE046285T2 (hu) 2020-02-28
TWI667026B (zh) 2019-08-01
KR102474467B1 (ko) 2022-12-05
CN105120844A (zh) 2015-12-02
EA201591728A1 (ru) 2016-01-29
BR112015023417A2 (pt) 2017-07-18
PT2970123T (pt) 2019-10-28
MX2015012429A (es) 2016-04-07
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
NZ750950A (en) 2020-09-25
JP2016513683A (ja) 2016-05-16
CL2015002708A1 (es) 2016-03-11
CN105209437A (zh) 2015-12-30
US20220153700A1 (en) 2022-05-19
RS61215B1 (sr) 2021-01-29
EP2968173A1 (en) 2016-01-20
RS59536B1 (sr) 2019-12-31
US9951015B2 (en) 2018-04-24
KR20150136063A (ko) 2015-12-04
EA031185B1 (ru) 2018-11-30
CA3147180A1 (en) 2014-09-25
JP6966590B2 (ja) 2021-11-17
PL2970123T3 (pl) 2020-03-31
EP2970123A1 (en) 2016-01-20
US20230044617A1 (en) 2023-02-09
CY1123633T1 (el) 2022-03-24
US11472773B2 (en) 2022-10-18
BR112015022857A2 (pt) 2017-07-18
PH12019500176A1 (en) 2020-11-04
BR112015023417B1 (pt) 2023-10-17
CY1122695T1 (el) 2021-03-12
AU2014240049B2 (en) 2018-07-19
RU2663663C2 (ru) 2018-08-08
PL2968173T3 (pl) 2021-03-08

Similar Documents

Publication Publication Date Title
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
IL274355B (en) Aza-pyridone compounds and their uses
HK1223351A1 (zh) 嘧啶衍生物作為激酶抑制劑
ZA201602220B (en) Heterocyclic compounds and uses thereof
HK1218512A1 (zh) 雜環化合物和其用途
GB201323008D0 (en) Compounds and uses thereof
HK1220363A1 (zh) 雜環化合物及其用途
GB201307233D0 (en) Compounds and uses thereof
GB201309180D0 (en) Compounds and Their Uses
GB201314610D0 (en) Compounds and their uses
GB201306248D0 (en) Compounds and their uses
GB201320161D0 (en) Compounds and their uses
GB201323005D0 (en) Compounds and uses thereof
AU2013902560A0 (en) Heterocyclic compounds and their use
GB201307202D0 (en) New compounds and uses
GB201307201D0 (en) New compounds and uses
GB201301734D0 (en) New compounds and uses
GB201300306D0 (en) Heterocyclic derivatives